Declaretimi 58: Dapagliflozin Cuts Heart Failure In Diabetes | Latest News RSS feed

Declaretimi 58: Dapagliflozin Cuts Heart Failure In Diabetes - Latest News


DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes

CHICAGO — Dapagliflozin (Farxiga/Forxiga, AstraZeneca) showed a nonsignificant trend toward a reduced rate of major adverse cardiac events (MACE) but significantly reduced hospitalization for heart fa... read more

Farxiga gets positive result in DECLARE-TIMI 58

"The DECLARE-TIMI 58 results offer compelling evidence that dapagliflozin helps to address an important medical need among a diverse group of patients with type-2 diabetes by reducing the composite of ... read more

Diabetes Drug Prevents Heart Failure

In the largest trial to date to assess cardiovascular outcomes for an important class of diabetes ... heart attack or heart failure. Results of the Dapagliflozin Effect on CardiovascuLAR Events – Thro... read more

Looking for another news?


Diabetes medication reduces risk of heart failure hospitalization

In the largest trial to date to assess cardiovascular outcomes for an important class of diabetes ... of heart attack or heart failure. Results of the Dapagliflozin Effect on CardiovascuLAR Events - T... read more


Dapagliflozin May Lower Heart Failure Hospitalizations in Patients With Diabetes

2 Despite these findings, dapagliflozin 10mg once per day was associated with lower rates of cardiovascular death or hospitalization for heart failure (HF ... placebo-controlled phase 3 trial (DECLARE ... read more

FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial

--(BUSINESS WIRE)--AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin ... with type 2 diabetes have a two-t... read more

Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

The big news, however, is what heart failure specialists have wondered about for some time—dapagliflozin ... Diabetes Association and the European Society of Cardiology to revise guidelines for patien... read more

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

CHICAGO, IL—DECLARE-TIMI 58, a trial of the ... risk factors or with manifest heart failure—further research is needed. Wiviott SD, Bonaca MP, Mosenzon O, et al. Dapagliflozin and cardiovascular outco... read more

AHA: Mixed Results with Dapagliflozin in T2D Patients

It is widely known that patients with type 2 diabetes are at an increased risk for adverse outcomes related to ASCVD, heart failure ... The phase III DECLARE-TIMI 58 trial assessed "the effects of dap... read more

Farxiga cuts hospitalisation for heart failure or CV death, study shows

“The DECLARE-TIMI 58 results offer compelling evidence that dapagliflozin helps to address an important medical need among a diverse group of patients with type-2 diabetes by reducing the composite of ... read more

FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabete...

AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin ... with diabetes, of whom those with type 2 diabetes ha... read more

New CARMELINA Analysis: No Heart Failure Risk With Linagliptin

But a preplanned analysis of heart failure ... the DECLARE TIMI 58 trial, in which more than 17,000 patients with type 2 diabetes, of whom 10,000 were free from cardiovascular disease at baseline, wer... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us